Genea Biocells has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to GBC0905 for the treatment of facioscapulohumeral muscular dystrophy (FSHD). GBC0905 is a drug that blocks the damaging DUX4 protein. This designation gives Genea Biocells certain financial benefits that will help to lower the cost of developing GBC0905. The company is currently seeking funds to advance GBC0905 to clinical trials.
For more information, read Genea Biocells’ press release.